Eli Lilly and Company (NYSE:LLY) Stock Gets Price Target Boost from Jefferies Financial Group

Eli Lilly and Company (NYSE:LLY) had its price target upped by analysts at Jefferies Financial Group from $1,610.00 to $1,700.00 in a report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Jefferies Financial Group‘s price target suggests a potential upside of 20.29% from the stock’s current price.

LLY has been the topic of a number of other research reports. Wells Fargo & Company raised their price target on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. UBS Group raised their target price on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a report on Friday, October 30th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,650.00 price target on shares of Eli Lilly and Company in a research report on Friday, October 30th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $1,450.00 price target on shares of Eli Lilly and Company in a research note on Monday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,416.64.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $59.22 during mid-day trading on Monday, reaching $1,413.22. 3,760,490 shares of the company traded hands, compared to its average volume of 2,967,246. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,453.00. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The stock has a fifty day simple moving average of $1,215.24 and a 200-day simple moving average of $1,101.16. The firm has a market cap of $1.33 trillion, a PE ratio of 45.87, a price-to-earnings-growth ratio of 1.62 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company’s quarterly revenue was up 38.6% on a year-over-year basis. During the same period in the previous year, the firm posted $7.02 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Coastal Bridge Advisors LLC purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $2,959,000. Birinyi Associates Inc. lifted its position in shares of Eli Lilly and Company by 32.6% in the 3rd quarter. Birinyi Associates Inc. now owns 1,460 shares of the company’s stock worth $1,689,000 after purchasing an additional 359 shares during the period. Mosaic Family Wealth Partners LLC raised its stake in Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock worth $4,144,000 after buying an additional 1,430 shares in the last quarter. Heritage Investors Management Corp lifted its holdings in Eli Lilly and Company by 6.5% during the third quarter. Heritage Investors Management Corp now owns 11,774 shares of the company’s stock worth $13,624,000 after buying an additional 718 shares during the period. Finally, Capital Investment Advisors LLC increased its holdings in shares of Eli Lilly and Company by 51.3% in the 3rd quarter. Capital Investment Advisors LLC now owns 44,851 shares of the company’s stock valued at $51,896,000 after acquiring an additional 15,214 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: In a Phase 3 trial, Foundayo reduced sleep-apnea breathing interruptions by up to an average of 44% after 52 weeks; up to 32% of participants achieved remission or mild disease. Lilly also reported improvements in oxygen-related measures and plans to seek FDA approval for obstructive sleep apnea by year-end 2026. A new indication could broaden the pill’s commercial opportunity beyond weight loss. Reuters article
• Positive Sentiment: Jefferies raised its LLY price target to $1,700 from $1,610, adding to the positive reaction to the trial results. Yahoo Finance article
• Positive Sentiment: Lilly’s agreements with Hims & Hers and LifeMD will offer eligible U.S. adults digital access to branded Zepbound and Foundayo through telehealth and prescription fulfillment, potentially widening the company’s reach. Yahoo Finance article
• Negative Sentiment: The FDA issued a warning about a potential increased risk of a serious eye condition associated with GLP-1 medicines, including weight-loss drugs. The safety alert could weigh on sentiment toward Lilly’s class of treatments, though the provided report does not quantify any effect on use or sales. Reuters article

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.